帕罗西汀联合丁螺环酮治疗抑郁症的对照研究

COMPARATIVE STUDY OF PAROXETINE COMBINED WITH BUSPIRONE IN THE TREATMENT OF DEPRESSION

目的探讨帕罗西汀联合丁螺环酮治疗抑郁症的疗效及安全性。方法将80例抑郁症患者随机分至研究组及对照组,每组40例。研究组应用帕罗西汀合并丁螺环酮治疗,对照组单用帕罗西汀治疗,观察8周。在治疗前及治疗后应用HAMD-17、HAMA及TESS量表评定疗效和不良反应。结果与治疗前比较,治疗后两组HAMD-17、HAMA评分均有较大幅度下降(P <0.01),研究组下降幅度为大于对照组(P <0.01);两组临床疗效比较差异有统计学意义(U=2.164,P <0.05);而两组不良反应比较无统计学意义(P>0.05)。结论帕罗西汀合并丁螺环酮治疗抑郁症的疗效优于单用帕罗西汀治疗,两者安全性相当。

Objective To explore the efficacy and safety of paroxetine combined with buspirone in the treatment of depression.Methods 80 patients with depression were randomly assigned to the study group and the control group(40 in each group).The study group was treated with paroxetine combined with buspirone,and the control group was treated with paroxetine alone for 8 weeks.The HAMD-17,HAMA,and TESS scales were used to assess efficacy and adverse effects before and after treatment.Results Comparing with the results before treatment,the HAMD-17 and HAMA scores of the two groups decreased significantly after treatment(P<0.01),and the decrease of the study group was greater than that of the control group(P<0.01).There was a statistically significant difference between the two groups(U=2.164,P<0.05).There were no significant differences between the two groups(P>0.05).Conclusion The efficacy of paroxetine combined with buspirone in the treatment of depression is superior to that of paroxetine alone.The safety of the two is comparable.